Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120 - Wikidata - awgldk - TriplyDB

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

http://www.wikidata.org/entity/Q33374701

about

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1 Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition Single domain antibodies: promising experimental and therapeutic tools in infection and immunity Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency.Fluorescent labelling of the actin cytoskeleton in plants using a cameloid antibody.Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1 Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.Phages and HIV-1: from display to interplay.Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity.The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.Single domain antibody multimers confer protection against rabies infection.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Germlining of the HIV-1 broadly neutralizing antibody domain m36 Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.Monoclonal antibody-based candidate therapeutics against HIV type 1.MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120 Neutralizing antibodies to HIV-1 induced by immunization.CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.Nanobody; an old concept and new vehicle for immunotargeting.HIV sexual transmission and microbicides.Biotechnological applications of recombinant single-domain antibody fragments.Specific microbicides in the prevention of HIV infection.Candidate antibody-based therapeutics against HIV-1.Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

P2860

Q24635002-1BBE604E-5945-477D-8BE2-3CB79B8CEE1F Q27322403-8641748B-7508-4545-B323-C5A1EBF59110 Q27661588-2A947011-B342-48AC-90EA-0CCE0B4B7FD6 Q27676864-F93ED6E2-3D03-46CF-ABE6-A018891BB8BD Q28248678-AEF0C8A4-E0CB-439C-9820-86E82AB20C6D Q28302768-55D450B8-4825-4485-A655-B78AEF86DA52 Q28741431-68040627-FF5B-4B91-BC21-5F6A66556556 Q29619511-09FFD9B7-5633-4B7B-ADBA-D211097691D4 Q30365366-0E615FAE-35B5-463B-A7A1-101A498B365C Q30579087-914D5B7C-2156-4F41-8CD6-3F18734A7BA0 Q33558279-A6EFD5AD-27E5-4EFB-BEA1-8A4FBF9633BE Q33657941-FD716923-27B2-45AA-84CC-6A48E868544A Q34099149-371F175B-C583-426F-8A7A-6645C1F881E0 Q34174815-FAC10EF6-97A9-4CAC-BD6B-04D089ACAB8E Q34206171-6C7C6B35-DAFB-4AAD-99FB-294715127BBF Q34220190-8B067C45-BF95-411C-BB49-59F84B8B802E Q34273397-4BBECE52-22EA-48CF-8643-5E696998F759 Q34284855-D9F694E9-3F3C-41AA-BC15-50911329F845 Q34522657-E376DE79-79D5-4C79-801F-55C86DCF3507 Q34776841-9F5FF24F-A520-41F6-8AF3-57402BC43CF0 Q34851484-EEA90288-7D9A-4267-B6C1-7C0F1768B17C Q34971008-2EA1D919-06B8-4E06-8A9A-9F95EA8F057F Q35155775-94118D8C-09EE-4881-9FF4-8F66D2DEE66D Q35171173-8190C56A-B754-4A2F-BA59-419DD796B575 Q35677620-9970FCBA-589B-4678-8709-7943B94CB42A Q35904501-D05900C9-2F41-40A3-BDE3-48ED129F664C Q36127736-0B961E36-95A5-4FE6-8E74-AD289152A962 Q36250325-FFAE739E-7C41-4C6F-9DB4-FFCDFE04B02E Q36319309-A9B3B239-3941-407D-931E-15A893E313F9 Q36559665-8DBBC730-6034-4DB7-B74C-34769C80A4F8 Q36603515-5F8FBF11-636E-48A7-8DCC-6FA54D4B2F82 Q36810796-EFE78021-61C2-498B-ACD1-7EFBE8AE5691 Q37346068-8DD509AA-FE75-4706-A9DB-F324A4CD4FBF Q37829737-5DD32C85-B3A4-40E4-8C5A-A1FAB9EBC3DE Q37853935-89525374-1465-44A9-A992-D5B97E96D503 Q37887077-F9B7A3AA-E3B8-4381-9983-CA208FBA6A0B Q37932048-1BEB56B6-E518-4A1E-BCA1-261CF5BB291A Q37998496-F1DAE18E-0263-44FA-95CC-5B269A0C4C6F Q38072056-5A5A5A71-3FEE-4398-821C-5878680620F1 Q38206519-362051EB-843F-4BDD-8F6E-575FE669F7B6

P2860

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

http://www.wikidata.org/entity/Q33374701

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@ast

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@en

type

label

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@ast

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@en

prefLabel

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@ast

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@en

P1433

Q33374701-2C30F8F5-8121-45CC-8878-825BF7354B35

P1476

Q33374701-74C8C983-D124-4BFA-90E7-5F517BEAA9D7

P2093

Q33374701-050263D4-9FD8-446C-97C2-DAFB002C1A9F

Q33374701-05A8BC77-260B-471D-B3B1-4A5334B5E2D4

Q33374701-1F625EC4-E6E2-4974-A713-A06545452587

Q33374701-2D4B80BC-C0DF-4648-9984-BCFB6E39D19F

Q33374701-60BF5077-820B-493D-8F85-AC723A60B224

Q33374701-6922FA40-BCEC-4DFD-B12D-619D8ABBFB1C

Q33374701-6A6AFDB7-9A43-42C1-B98B-53A4EF2F1C98

Q33374701-883FF266-B14B-44CF-88E0-6567D03035C4

Q33374701-91336D1D-6F5C-4181-96E2-10F8897BCD5E

Q33374701-ADC49ED3-3375-47DF-806C-712A8EC20A10

P2860

Q33374701-040A7B60-63CB-40B7-A1B0-1F6FB7C18F2E

Q33374701-0669B058-A400-40CA-86E0-BCC9BC4B5E7D

Q33374701-07E16353-DD38-4FC9-95AC-7A18BC3ABC10

Q33374701-0DE38B48-ADA0-45B2-A1D2-930DB47F0B5D

Q33374701-0EBBC22C-293D-4F41-8B33-10FF3D4F466C

Q33374701-11ACAAE1-BBBD-4130-8406-43FB6AED5E87

Q33374701-14BE7FEC-1FC2-4049-A2CF-4A91EE7A877C

Q33374701-17E10896-674D-4141-AB8A-9A1E9F8FFF70

Q33374701-19357CBA-862A-4B25-B96E-0935A6D99FD0

Q33374701-1C23F398-06C1-4CD3-9AB1-5A11EBB1129B

P304

Q33374701-B4E0DF21-2C0B-4571-AC15-D5026EBC1287

P31

Q33374701-3D4ABFF2-67E7-4A0C-880C-0E26B47AABBA

P356

Q33374701-D0FFD58D-752B-42F1-89C8-22256800E5D1

P433

Q33374701-0BE62195-6299-436A-91D2-1A667C711E87

P478

Q33374701-1679D5A1-E9DA-4699-8260-FA50497A6B84

P577

Q33374701-D97FD4C3-539C-422C-BD88-BD5D827AFFEF

P698

Q33374701-BB923676-C627-4DF4-9EB3-38BDB5F4E03A

P921

Q33374701-4EBC2EBC-D3C0-4DC4-B64E-692F75B3720C

P932

Q33374701-60DB8E9E-0E86-46B8-85F0-0BAA519F695D

P356

P1433

Journal of Virology

P1476

Llama antibody fragments with ...... high affinity for HIV-1 gp120

@en

P2093

Agnieszka Szynol

http://www.w3.org/2001/XMLSchema#string

Aine McKnight

http://www.w3.org/2001/XMLSchema#string

Anna Forsman

http://www.w3.org/2001/XMLSchema#string

Bart Hoorelbeke

http://www.w3.org/2001/XMLSchema#string

Charles Kelly

http://www.w3.org/2001/XMLSchema#string

Els Beirnaert

http://www.w3.org/2001/XMLSchema#string

Hans de Haard

http://www.w3.org/2001/XMLSchema#string

Karolin Hijazi

http://www.w3.org/2001/XMLSchema#string

Marlén M I Aasa-Chapman

http://www.w3.org/2001/XMLSchema#string

Robin A Weiss

http://www.w3.org/2001/XMLSchema#string

P2860

Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Energetics of the HIV gp120-CD4 binding reaction

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro

Structural definition of a conserved neutralization epitope on HIV-1 gp120

A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme

Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding

P304

12069-12081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01379-08

http://www.w3.org/2001/XMLSchema#string

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18842738

http://www.w3.org/2001/XMLSchema#string

P921

P932

2593325

http://www.w3.org/2001/XMLSchema#string